[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"irritable-bowel-syndrome-with-constipation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:irritable-bowel-syndrome-with-constipation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100479184","phase-2-home-transcutaneous-electrical-acustimulation-tea-100479184",false,"NCT05519683","Home Transcutaneous Electrical Acustimulation (TEA)","Effects of Home-based TEA for Abdominal Pain in Patients With Irritable Bowel Syndrome (IBS)","Home-TEA","Inclusion Criteria:\n\n* Those with ongoing and symptomatic Irritable Bowel Syndrome with Constipation (IBS-C)\n* Significant mean worst abdominal pain severity (as defined by the study protocol, which will be shared with results reporting) on a Visual Analog Scale (VAS) pain score during the Phase-in period\n* Symptoms present at least 1 day\u002Fweek in the last 3 months with symptom onset at least 6 months prior to the diagnosis.\n* Abdominal pain is not adequately relieved at the time of screening and the time of randomization.\n\nExclusion Criteria:\n\n* Unrelated active disorder which may involve abdominal pain, such as inflammatory bowel disease, diabetes or unstable thyroid disease.\n* Pregnancy, plans to become pregnant, or lactation. Any potential patient of child-bearing potential will complete a pregnancy test at Visit 1 and if the test is positive that individual will be excluded from future participation.\n* Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study\n* A history of abdominal surgery (other than cholecystectomy or appendectomy)\n* Active use of prucalopride, domperidone, alosetron, tegaserod, warfarin, antipsychotic (e.g., Seroquel, Risperdal), antidiarrheal, or frequent (\\>2 days\u002Fweek) use of opioid or antispasmodic medication. Those who frequently use Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) will also be excluded.\n* Ongoing use of Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), or any other serotonin-active medications, including tricyclic antidepressants (TCAs). Individuals on chronic SSRI therapy, including escitalopram, at the initial evaluation will not be enrolled in the study.\n* Inability to avoid the following medications: tricyclic antidepressants, Monoamine Oxidase (MAO) inhibitors including, intravenous methylene blue, linezolid, and pimozide, as well as triptans, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort. - - Participants will be informed that MAO inhibitors cannot be used within 14 days of starting or stopping escitalopram.\n* Known hypersensitivity to escitalopram or citalopram including any of the inactive ingredients of these formulations.\n* Known allergy to adhesive Electrocardiogram (ECG) electrodes.\n* Known angle-closure glaucoma, bipolar disorder, history of seizures or prior suicide attempt or known suicidal thoughts.\n* Known QTc prolongation or receiving scheduled therapy with a medication associated with prolongation of QTc (screening to be completed at recruitment as detailed above).","ALL","18 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","This study will assess the efficacy of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.",[28],"Irritable Bowel Syndrome With Constipation",[30,31,32,33,34],"Irritable Bowel Syndrome with Constipation","Constipation","Irritable Bowel Syndrome","Colon, Irritable","Irritable Colon","RECRUITING","2026-09-15",{"date":38,"type":39},"2026-09-17","ACTUAL",{"date":41,"type":39},"2022-11-02",{"date":43,"type":21},"2027-03",{"name":45,"class":46},"University of Michigan","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":47},"100500448","a-study-of-virtual-reality-and-linaclotide-for-ibs-c-100500448","NCT05796388","A Study of Virtual Reality and Linaclotide for IBS-C","A Pilot Study to Evaluate the Efficacy and Safety of Virtual Reality in Combination With Linaclotide for the Treatment of Adults With IBS and Constipation Predominance","IBSC-VR","Inclusion Criteria:\n\n* Adult men and women (18-70) who meet Rome IV criteria for IBS-C.\n* Patients will be required to score below 65 points on the IBS Quality of Life (IBS-QOL) instrument, indicating a score consistent with at least moderate HRQOL (Health-related quality of life) impairment.\n\nExclusion Criteria:\n\n* Patients will be excluded from the study if they have a comorbid disorder that may confound the diagnosis of IBS, including celiac disease, inflammatory bowel disease, autoimmune disorders that affect the GI system, history of bowel resection, HIV\u002FAIDS, diabetes with HgA1c \\>7.0, neuroendocrine tumors, microscopic colitis, lactase deficiency, eosinophilic bowel disease, acute intermittent porphyria, or any other condition that a licensed physician believes can mimic IBS symptoms and undermine diagnostic certitude.\n* Patients with severe depression, defined as a score equal to or greater than two standard deviations (SDs) on the NIH PROMIS depression scale, or those with suicidal ideations, will also be excluded and provided with standard resources to support their mental health and referred back to their primary care provider, a member of the study team will follow up with the PCP to ensure the communication was received.\n* Patients using regular doses of opioid medications will also be excluded given the often-severe impact of opioids on GI motility and potential for pharmacological visceral hyperalgesia.\n* Patients will also be excluded from the study if they do not meet Rome IV criteria for IBS-C,\n* have a known seizure disorder,\n* if symptoms are thought to represent an organic disorder,\n* if they have had prior surgery to the colon,\n* if symptoms represent a known pelvic floor disorder,\n* if the patient is abusing alcohol,\n* or if the patient cannot actively participate in the study for any other reason (e.g., inability to understand English as the VR program is in English only).\n* Patients previously treated with linaclotide who reported side effects,\n* those currently on linaclotide (any dose),\n* and those who did not note an improvement in IBS-C symptoms in the past while on linaclotide will also be excluded.","70 Years",{"count":58,"type":21},65,[60],"NA","The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication) and immersive virtual reality (VR) therapy compared to those treated with linaclotide and sham (placebo) VR therapy.",[28],[64,65],"Virtual reality","IBS-C","2026-07-27",{"date":68,"type":39},"2026-07-29",{"date":70,"type":39},"2024-05-31",{"date":72,"type":21},"2026-10",{"name":74,"class":46},"Mayo Clinic"]